Regulatory Story
Go to market news section View chart   Print
The MedicX Fund Limited   -  MXF   

Notice of dividend

Released 17:31 01-Nov-2018

RNS Number : 1098G
The MedicX Fund Limited
01 November 2018



Press Release

For immediate release                                                                                    

1 November 2018


MedicX Fund Limited

("MedicX", "the Fund" or "the Company")


Notice of dividend


The Directors have approved a quarterly dividend of 1.51p per Ordinary Share in respect of the period 1 July 2018 to 30 September 2018 (the "December 2018 Dividend"). This will bring the total dividends declared in respect of the financial year ended 30 September 2018 to 6.04p per Ordinary Share, an increase of 0.67% over the dividends totalling 6.00p declared for the previous year ended 30 September 2017. The dividend will be paid on 31 December 2018 to ordinary shareholders on the register as at 16 November 2018 (the "Record Date"). The corresponding ex-dividend date will be 15 November 2018.


This quarterly dividend will comprise 30% (0.453p) Property Income Distribution ("PID") and 70% ordinary dividend (1.057p). For shareholders who qualify for gross payment of distributions, forms to register for gross PIDs are available on the Company's website at declarations must be returned to the Company's registrar, Link Asset Services, Corporate Actions, The Registry, 34 Beckenham Road, Beckenham, Kent, BR3 4TU to arrive by the Record Date. Please click on the above link or refer to the Company's website to obtain an eligibility declaration form.


The Company is offering qualifying shareholders the opportunity to take new ordinary shares in the Company, credited as fully paid, in lieu of the net cash dividend to be paid on 31 December 2018, by participating in the Scrip Dividend Scheme (the "Scheme") previously put in place by the Company on 5 May 2010. Following the Company's notice of entry into the UK REIT regime effective from 1 October 2017, the Scrip Dividend Scheme Document was updated to illustrate to shareholders the mechanics of the possibility of a scrip alternative being offered for a dividend which is paid partly or fully as a Property Income Distribution ("PID") as well as a link to where shareholders can elect online to receive their dividend in the form of new shares rather than cash.


The scrip calculation price in respect of the December 2018 Dividend is due to be calculated and published on or around 22 November 2018. If the Company's shares are trading at a price below prevailing EPRA Net Asset Value ("NAV") per share on the five consecutive business days commencing on the ex-dividend date of 15 November 2018, such that the scrip calculation price would be at a discount to the prevailing NAV per share, the Directors expect to exercise their right to suspend the Scrip Dividend Alternative for the December 2018 Dividend, pursuant the Scheme Document. In this case, all shareholders entitled to receive a dividend would receive their dividend in cash.


Subject to the paragraph above, the option to participate will be available to shareholders until 6 December 2018 (the "election date").  Further information on the Scheme, together with a copy of the Scheme Document (which contains the terms and conditions of the Scheme) and relevant mandate form document, is available for inspection at the National Storage Mechanism (, or through the Scrip Dividend portal on the Company's website (





For further information please contact:


Octopus Healthcare Adviser Ltd                                     +44 (0) 345 0404 5555


Octopus Healthcare                                                      +44 (0) 20 3142 4820

Mike Adams, Executive Chairman


Maitland/AMO                                                              +44 (0) 20 7379 5151

Andy Donald/Freddie Barber



Information on MedicX Fund Limited


MedicX Fund Limited ("MXF", "MedicX Fund", the "Fund" or the "Company", or together with its subsidiaries, the "Group") is the specialist primary care infrastructure investor in modern, purpose-built primary healthcare properties in the United Kingdom and Ireland, listed on the London Stock Exchange, with a portfolio comprising 165 properties.


The Investment Adviser to the Company is Octopus Healthcare Adviser Ltd, which is part of the Octopus Healthcare group. Octopus Healthcare invests in and develops properties as well as creating partnerships to deliver innovative healthcare buildings to improve the health, wealth and wellbeing of the UK. It currently manages over £1.4 billion of healthcare investments across a number of platforms, with a focus on five core areas: GP surgeries, care homes, special education schools, retirement housing and private hospitals. Octopus Healthcare is part of the Octopus group, a fast-growing UK fund management business with leading positions in several specialist sectors including healthcare property, energy, property finance and smaller company investing. Octopus manages £8.0 billion of funds for more than 50,000 retail and institutional investors as well as supplying energy to more than 320,000 customers.


Octopus Healthcare Adviser Ltd is authorised and regulated by the Financial Conduct Authority.


The Company's website address is Neither the contents of the Company's website nor the contents of any website accessible from hyperlinks on the Company's website (or any other website), nor the contents of any website accessible from hyperlinks within this announcement, are incorporated into, or forms part of, this announcement.


The Company's Legal Entity Identifier is 2138008POF35FTNFCB25


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply.


Notice of dividend - RNS